Vistagen Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period: This quarterly report covers the three and six months ended September 30, 2021—VistaGen’s fiscal second quarter and first half of fiscal 2022. The company is a clinical-stage biopharmaceutical developer with no approved products or recurring product-sales revenue. Its CNS pipeline includes PH94B for anxiety disorders, PH10 for depression, and AV-101, which it plans to study with probenecid.
Key financial metrics
| Metric | Three months ended September 30, 2021 | Six months ended September 30, 2021 |
|---|---|---|
| Revenue | $358,000 | $712,100 |
| Research and development expense | $10.1 million | $15.7 million |
| General and administrative expense | $3.1 million | $5.6 million |
| Net loss | $12.8 million | $20.5 million |
| Net loss attributable to common stockholders | $13.2 million | $21.3 million |
| Basic and diluted loss per share | $0.07 | $0.11 |
- Cash and liquidity: Cash and cash equivalents were $93.6 million at September 30, 2021, down from $103.1 million at March 31, 2021. Management stated the balance was expected to fund planned operations for well beyond 12 months after issuance of the financial statements.
- Cash flow, six months: Operating activities used $17.6 million; investing activities used $0.2 million; financing activities provided $8.3 million. Cash declined by $9.5 million.
- Debt and obligations: Total liabilities were $19.8 million, including $3.5 million of operating lease obligations and $7.0 million of accrued Series B preferred dividends. The filing reports no material conventional borrowing balance; the PPP loan had been repaid in December 2020.
- Revenue and margins: Revenue was sublicense revenue under the AffaMed PH94B agreement, recognized from its prior $5.0 million upfront payment. Revenue was immaterial relative to operating expenses; the filing does not present a gross margin measure.
Material changes versus the prior comparable period
- Second-quarter revenue rose to $358,000 from $334,000; first-half revenue was $712,100 versus $334,000 a year earlier.
- Second-quarter operating expenses increased to $13.2 million from $3.6 million, and net loss widened to $12.8 million from $3.3 million. For the first half, operating expenses rose to $21.3 million from $6.7 million and net loss to $20.5 million from $6.4 million.
- Management attributed higher costs primarily to initiating and conducting PH94B’s PALISADE Phase 3 trials, other PH94B/PH10 development and manufacturing work, expanded staffing and compensation accruals, and pre-commercialization research. First-half G&A also included a $232,000 noncash write-off of deferred offering costs after termination of the Lincoln Park equity-line agreement.
- Financing included $4.25 million from warrant exercises and approximately $4.4 million in gross ATM stock-sale proceeds during the six months. Shares issued increased from 180.8 million at March 31 to 196.6 million at September 30; additional options and warrants may contribute to future dilution.
Outlook, commentary, risks, and unusual items
- Development plans: Management planned to continue PH94B’s PALISADE Phase 3 program and exploratory Phase 2A work; prepare or initiate PH10 Phase 2B development in major depressive disorder; and prepare an AV-101/probenecid Phase 1B drug-interaction study. The company anticipated PALISADE-1 topline results in mid-2022 and PALISADE-2 results later in 2022. A potential PH94B U.S. NDA submission was discussed for mid-2023, conditional on successful Phase 3 results.
- Funding: VistaGen has no recurring product revenue and expects continuing losses and negative operating cash flow. It may seek additional equity, collaborations, grants, or other funding; availability and terms are uncertain, and equity financing could dilute shareholders. Management cautioned that inability to raise capital when needed could force development delays or curtailments.
- Clinical and operating risks: Key risks include clinical-trial failure or delay, regulatory approval uncertainty, reliance on third-party manufacturers and CROs, supply disruptions, competition, intellectual-property challenges, and COVID-19 effects on suppliers, trial recruitment, and operations.
- Unusual and subsequent items: After quarter-end, 895,781 warrants were exercised for approximately $1.13 million; Series C preferred shares converted into 2,318,012 common shares; and the headquarters lease was extended through July 31, 2027. The lease amendment’s effects were not reflected in the September 30 financial statements.
- Controls and contingencies: Management concluded disclosure controls were effective at quarter-end, but previously identified material weaknesses in segregation of duties and accounting software remained under remediation. The filing reports no legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Progress, enrollment, safety, and topline timing for PALISADE-1 and PALISADE-2, and whether results support the stated NDA timetable.
- Actual cash burn and runway as Phase 3 and other development programs advance; the company’s financing needs and any further ATM or other share issuance.
- Clinical and regulatory milestones for PH10 and AV-101 with probenecid, including whether planned studies commence on schedule.
- Potential dilution from outstanding options and warrants, preferred-stock rights and dividends, and post-quarter conversions or exercises.
- Whether remediation of the reported internal-control material weaknesses is completed and independently validated.
- Effects of the extended lease and any COVID-19-related supply, manufacturing, or clinical-trial disruption.